Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Remco J Molenaar, MDPhD, Tomas Radivoyevitch, Aaron T. Gerds, MDMS, Aziz Nazha, Hetty E. Carraway, MD MBA, Anjali S. Advani, MD, Matt Kalaycio, MD, Navneet S. Majhail, MD MS, Jaroslaw P. Maciejewski, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH

Blood (2018) 132 (Supplement 1): 900.

https://doi.org/10.1182/blood-2018-99-118207

Published: 2018

Journal Articles

Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Teodora Kuzmanovic, Bhumika J. Patel, MD, Srinivasa Reddy Sanikommu, MD, Yasunobu Nagata, Hassan Awada, MD, Cassandra M. Hirsch, Bartlomiej P. Przychodzen, Remco J Molenaar, MD PhD, Babal K. Jha, Sudipto Mukherjee, MD PhD MPH, Anjali S. Advani, MD, Aziz Nazha, Aaron T. Gerds, MD MS, Hetty E. Carraway, MD MBA, Mikkael A. Sekeres, MD MS, Jaroslaw P. Maciejewski, Tomas Radivoyevitch, PhD

Blood (2018) 132 (Supplement 1): 3084.

https://doi.org/10.1182/blood-2018-99-119950

Published: 2018

Journal Articles

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

Remco J Molenaar, Tomas Radivoyevitch, Aziz Nazha, MD, Anjali S. Advani, MD, Aaron T. Gerds, MDMS, Jaroslaw P. Maciejewski, PhD MD FACP, Navneet S. Majhail, MD MS, Mikkael A. Sekeres, MD MS, Matt Kalaycio, MD, Sudipto Mukherjee, MD PhD MPH

Blood (2017) 130 (Supplement 1): 2871.

https://doi.org/10.1182/blood.V130.Suppl_1.2871.2871

Published: 2017

Journal Articles

High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations

Remco J Molenaar, Tomas Radivoyevitch, PhD, Mikkael A. Sekeres, MD MS, Sudipto Mukherjee, MD PhD MPH, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 421.

https://doi.org/10.1182/blood.V130.Suppl_1.421.421

Published: 2017

Journal Articles

IDH1/2 -Mutated Acute Myeloid Leukemia Has Impaired DNA Damage Response and Is Sensitive to Monotherapy with the PARP Inhibitior Olaparib

Remco J Molenaar, Tomas Radivoyevitch, PhD, Yasunobu Nagata, MD PhD, Bartlomiej P. Przychodzen, MSc, Hideki Makishima, MD PhD, Hetty E. Carraway, MD MBA, Sudipto Mukherjee, MD PhD MPH, Mikkael A. Sekeres, MD MS, Cornelis van Noorden, PhD, Jaroslaw P. Maciejewski, PhD MD FACP

Blood (2017) 130 (Supplement 1): 568.

https://doi.org/10.1182/blood.V130.Suppl_1.568.568

Published: 2017

NARROW

Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations

IDH1/2 -Mutated Acute Myeloid Leukemia Has Impaired DNA Damage Response and Is Sensitive to Monotherapy with the PARP Inhibitior Olaparib

Email alerts

ASH Publications

American Society of Hematology

Is There an Increased Risk of ALL in Patients with First Cancers Treated with Radiotherapy and/or Chemotherapy?

Somatic Mutations in Therapy-Related Myeloid Neoplasms Are Influenced By Therapeutic Modality and Clonal Hematopoiesis of Indeterminate Potential

Atherosclerotic Arterial Disease-Related Mortality in Chronic Myeloid Patients Treated with Tyrosine Kinase Inhibitors

High Rates of Atherosclerotic Disease-Related Mortality in Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia Patients Associated with TET2-Mutations

IDH1/2 -Mutated Acute Myeloid Leukemia Has Impaired DNA Damage Response and Is Sensitive to Monotherapy with the PARP Inhibitior Olaparib

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only